Loading... 2 0 20 0 false
Credit Name
Matthew M K Chan
Full Name
Chan, Matthew M K
Loading... 3 0 20 0 false


Results 1-13 of 13 (Search time: 0.024 seconds).

Issue DateTitleAuthor(s)
1Oct-2020Platinum-containing regimens for triple-negative metastatic breast cancerChan, Matthew M K 
2May-2018Metastasis-specific patterns of response and progression with anti-PD-1 treatment in metastatic melanomaChan, Matthew M K 
3Aug-2017Dose individualization of sunitinib in metastatic renal cell cancer: toxicity-adjusted dose or therapeutic drug monitoringChan, Matthew M K 
4Apr-2016sFRP2 in the aged microenvironment drives melanoma metastasis and therapy resistanceChan, Matthew M K 
5Nov-2015Clinicopathologic features associated with efficacy and long-term survival in metastatic melanoma patients treated with BRAF or combined BRAF and MEK inhibitorsChan, Matthew M K 
6Nov-2015A phase III randomized trial of adding topical nitroglycerin to first-line chemotherapy for advanced nonsmall-cell lung cancer: the Australasian lung cancer trials group NITRO trialChan, Matthew M K 
7Oct-2015Ipilimumab-induced hypophysitis in melanoma patients: an Australian case seriesChan, Matthew M K 
8Sep-2015Clinical utility of ramucirumab in advanced gastric cancerChan, Matthew M K 
9Jun-2015Taxane-containing regimens for metastatic breast cancerChan, Matthew M K 
10Jan-2015Arthritis and tenosynovitis associated with the anti-PD1 antibody pembrolizumab in metastatic melanomaChan, Matthew M K 
11Oct-2014The nature and management of metastatic melanoma after progression on BRAF inhibitors: effects of extended BRAF inhibitionChan, Matthew M K 
12Jul-2014Symptomatic Histologically Proven Necrosis of Brain following Stereotactic Radiation and Ipilimumab in Six Lesions in Four Melanoma PatientsChan, Matthew M K 
13Jul-2006Long-acting beta2-agonists for poorly reversible chronic obstructive pulmonary diseaseChan, Matthew M K